Spots Global Cancer Trial Database for The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer
Official Title: The Clinical Research of Fourth Generation CART-cell Therapy in Refractory-Relapsed Ovarian Cancer
Study ID: NCT03814447
Conditions
Study Description
Brief Summary: The goal of this clinical trial is to study the safety and feasibility of anti- Mesothelin Chimeric Antigen Receptor T-Cell (MESO CAR-T cells) therapy for Refractory-Relapsed Ovarian Cancer
Detailed Description: Primary Objectives: 1. To determine the safety and feasibility of anti- MESO CAR-T cells therapy for Refractory-Relapsed Ovarian Cancer Secondary Objectives: 1. To access the efficacy of anti- MESO CAR-T cells in patients with ovarian cancer. 2. To determine in vivo dynamics and persistency of anti- MESO CAR-T cells 3. To assess the quality of life in patients with ovarian cancer after treatment with anti- MESO CAR-T cells.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Shanghai 6th People's Hospital, Shanghai, Shanghai, China
Contact Details
Name: Hui Zhao, doctor
Affiliation: Shanghai 6th People's Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
